TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04720976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be administered orally, variable dose.
Study: NCT06009952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryolipolysis and cavitation devices with vegan diet
Description: Cryolipolysis: In all cases of group A, (OPTIMIZED CRYOLIPOLYSIS 360 DEVICE, model: AF2000-02, made in china) uses a vacuum-based huge applicator (Cool Max) and vacuum medium applicators (either CoolCore or Cool- Curveþ) for the abdomen (30 minutes session twice monthly for three successive3 months).~•Cavitation: in all cases of group B, (CAVITATION DEVICE, Item No.:AU61, Made in china) of 45 KHz frequency (30 min twice weekly for three successive3 months).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryolipolysis and cavitation devices with vegan diet
Description: Cryolipolysis: In all cases of group A, (OPTIMIZED CRYOLIPOLYSIS 360 DEVICE, model: AF2000-02, made in china) uses a vacuum-based huge applicator (Cool Max) and vacuum medium applicators (either CoolCore or Cool- Curveþ) for the abdomen (30 minutes session twice monthly for three successive3 months).~•Cavitation: in all cases of group B, (CAVITATION DEVICE, Item No.:AU61, Made in china) of 45 KHz frequency (30 min twice weekly for three successive3 months).
Study: NCT05218759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: anlotinib administration at a dose of 10 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: anlotinib administration at a dose of 10 mg daily
Study: NCT04389411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg
Description: 10mg oral Montelukast will be taken daily for 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast 10mg
Description: 10mg oral Montelukast will be taken daily for 60 days
Study: NCT05176093

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engensis
Description: Lyophilized biologic to be reconstituted containing Engensis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injectable Liquid
Study: NCT05543785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 50 ml normal saline without drugs will be injected
Study: NCT05624099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: 200mg intravenous drip d1q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel drugs
Description: 150mg/m2 d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum drug
Description: Cisplatin, carboplatin, nedaplatin and other platinum drugs

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Dose: 5040cGy/28f
Study: NCT05771272

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sit and Reach Test
Description: To conduct the test, a box measuring 32 centimeters in height, 45 centimeters in width, and 35 cm in length, and the upper surface of the box was 15 cm longer than the area on which the feet rest. The participant is positioned on the ground with both legs fully extended, separated by shoulder width, and flat on the box. The participant positioned themselves with one hand on top of the other, knees fully extended, stretched as far forward as they could, sliding their hands across the ruler's top, and kept that posture for at least two seconds. The end location of the fingertips on or approaching the ruler was measured in centimeters to get the sit and reach score. Scores that are higher showed improved performance. The best result is recorded after the test was run three times.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Weight Bearing Lunge Test
Description: To conduct the test, with a tape measure on the floor, measure the distance from the big toe's end to the wall. Participants make a lunging motion forward until their knee hit on the wall. The participant's foot is positioned on the floor with the big toe and heel line aligned on the tape measure. To determine how close to the wall a subject could touch the wall with their knee while still keeping their heel in contact. The tape measure is then used to calculate the distance from the big toe's tip to the wall in centimeters. Increasing the distance indicates that the participant has less ankle dorsiflexion range
Study: NCT04720976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be administered orally, variable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be administered orally, variable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be administered orally, variable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be administered orally, variable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be administered orally, variable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be administered orally, variable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be administered orally, variable dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Binimetinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib will be administered orally.
Study: NCT04708782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil (6 mcg/breath) administered QID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treprostinil Ultrasonic Nebulizer
Description: Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treprostinil Ultrasonic Nebulizer
Description: Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Study: NCT06196892

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic BBr60
Description: Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BBr60.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic BBr60
Description: Collect patient fecal samples, test for 16S rRNA, and analyze the changes in the patient's gut microbiota before and after taking BBr60.
Study: NCT05204667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily
Description: (2 oral tablets 4 times/day up to 7 days (i.e., every 6 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily
Description: (2 oral tablets 6 times/day up to 7 days (i.e., every 4 hours±1 hour). Ingestion of the tablets can be helped with a small amount of water.
Study: NCT04945226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride 1mg Tablet
Description: Propecia Tablet 1mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3001
Description: Finasteride long acting injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3001
Description: Finasteride long acting injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3001
Description: Finasteride long acting injection
Study: NCT05844995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Naproxen Sodium
Description: Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
Study: NCT06468449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb power output training
Description: Lower limb power output training content:~Half squat up squat: 70%1R (6 repetitions × 5sets) + 5 knees jumps × 5 sets with an interval of 90 seconds；

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Force Combined Speed training
Description: Lower limb Force Combined Speed training content:~Rapid half squat : Optimal load (6 sets × 7 repetitions). Rest intervals between sets range from 2 to 5 minutes.
Study: NCT05479734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: A smartphone app (mHealth app) will deliver daily tailored messages with tips on monitoring and promoting child development and positive parenting tips.
Study: NCT06126770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The social norm intervention
Description: The intervention will target Married adolescent girls, their spouses, and elderly/influential community members. Thirty-six 2-hour weekly sessions will be conducted with MAGs. The session topics will be categorized into two broad headings: i) Health and life skills sessions covering, for example topics such as sex and gender, rights, marriages, SRHR, and ii) Business and entrepreneurship sessions.~Spouses of the MAGs will receive 20 2-hour bi-weekly sessions. A total of three 2-hour couples sessions will be held. Elderly women and influential community members will have three 2-hour bi-monthly sessions. In addition, MAGs with leadership qualities will be identified and trained to conduct campaigns and activism. They will also receive training on income generating.
Study: NCT04843891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [64]Cu Macrin
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [64]Cu Macrin
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [64]Cu Macrin
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [64]Cu Macrin
Description: Up to 15 mCi of \[68Ga\]CBP8 will be administered to each subject.
Study: NCT04965597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lapine T-Lymphocyte Immune Globulin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo bone marrow transplant
Study: NCT05996861

Intervention type: BEHAVIORAL
Intervention: ICU sleep protocol
Description: Adjusting sound intensity, as well as reducing noise: efforts will be made to minimize staff conversation volume during the night.~Earplugs will be offered, along with the provision of eye masks for lucid patients, and thermal comfort adjustments will be made, such as providing blankets and/or adjusting room temperature.~Dimming of lights starting from 10 PM. Reduced circulation of external services between 11 PM and 6 AM, and rationalization of sample collections and/or patient transfers between beds during the 11 PM to 6 AM interval.~Optimization of analgesics for better pain control; optimization of medication use during wakefulness when clinically feasible; adjustment of intervals for capillary blood glucose measurement; maintaining and/or resuming the use of chronic sleep medications. If the patient has been unable to sleep, a hypnotic medication will be offered.~Other considerations include suggesting ventilatory support measures for selected patients.
Study: NCT06399328

Intervention type: DIAGNOSTIC_TEST
Intervention: Surface Enhanced Raman Spectroscopy
Description: Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Serum samples were collected and placed in sterile tubes with subsequent freezing at -18°C. Immediately before analysis, samples were thawed at room temperature. For spectral analysis, each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried for 30 minutes. The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope (ADF U300, ADF, China). The spectra were excited in the near infrared range using a laser module with a center wavelength of 785 nm. Each of the obtained spectra represented a discrete set of 1700 parameters in the range of studied frequencies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Surface Enhanced Raman Spectroscopy
Description: Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Serum samples were collected and placed in sterile tubes with subsequent freezing at -18°C. Immediately before analysis, samples were thawed at room temperature. For spectral analysis, each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried for 30 minutes. The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope (ADF U300, ADF, China). The spectra were excited in the near infrared range using a laser module with a center wavelength of 785 nm. Each of the obtained spectra represented a discrete set of 1700 parameters in the range of studied frequencies.

Intervention type: DIAGNOSTIC_TEST
Intervention: Surface Enhanced Raman Spectroscopy
Description: Spectral measurements of blood serum were performed on a silver nanoparticle substrate. Serum samples were collected and placed in sterile tubes with subsequent freezing at -18°C. Immediately before analysis, samples were thawed at room temperature. For spectral analysis, each 1.5 μL serum sample was applied to a substrate with a layer of silver nanoparticles and dried for 30 minutes. The spectral characteristics of serum were analyzed using an experimental bench consisting of a spectrometric system and a microscope (ADF U300, ADF, China). The spectra were excited in the near infrared range using a laser module with a center wavelength of 785 nm. Each of the obtained spectra represented a discrete set of 1700 parameters in the range of studied frequencies.
Study: NCT05371535

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MatrixOssTM Bone Graft plus Bio-Gide membrane
Description: To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MatrixOssTM Bone Graft plus Bio-Gide membrane
Description: To verify the efficacy and safety of MatrixOssTM Bone Graft developed and manufactured by Collagen Matrix, Inc. for bone defect repair caused by tooth extraction.
Study: NCT05314946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No feeding tube placed
Description: The experimental arm will forego placement of a feeding tube.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of a percutaneous feeding tube
Description: The standard arm will have a feeding tube placed (G-tube or GJ-tube by IR; or surgically placed J-tube)
Study: NCT06208241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state and suspended in a solution containing DMSO.
Study: NCT05493995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab 200 mg administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125mg/m\^2，administered intravenously on days 1 and 8 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1.0g/m\^2, administered intravenously on days 1 and 8 of every 21-day cycle.
Study: NCT05770466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 (Ropeginterferon alfa-2b)
Description: 1. Name: P1101 (Ropeginterferon alfa-2b)~2. Dosage form: pre-filled syringe~3. Strength: A single dose of 250 mcg/0.5 mL~4. Dosage and administration: 250 mcg per subcutaneous injection~5. Mechanism of action (if known): Interferon work by binding to specific membrane receptors on the cell surface which in turn induce a complex sequence of intracellular events. These events include the induction of particular enzymes, suppression of cell proliferation, inhibition of virus replication in virus infected cells and immunomodulating activities.~6. Pharmacological category: Antineoplastic and immunomodulating agents/ Immunostimulants/ Cytokines

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SOC
Description: SOC includes infection prevention and control measures, supportive care, dexamethasone, and antiviral agents. The SOC is based on the Taiwan Centers for Disease Control (CDC) guidance and investigator's discretion.
Study: NCT05800327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levilimab
Description: Subcutaneous or intravenous injection of levilimab with placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levilimab
Description: Subcutaneous or intravenous injection of levilimab with placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levilimab
Description: Subcutaneous or intravenous injection of levilimab with placebo.
Study: NCT06184334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solfenacin
Description: pills taken once day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: pills taken once day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 5mg
Description: pills taken once day
Study: NCT06501131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: full-spectrum light exposure
Description: Subjects will stay in a room with full spectrum light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific spectrum absence light exposure
Description: Subjects will stay in a room with ordinary LED light for 5 minutes. After 5 minutes wash-out period, altenate to the other arm.
Study: NCT05270772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T-19 Cells
Description: T cells were isolated from the PBMC of patients, transduced with lentivirus, expanded in vitro, and infused into patients. The escalated doses include 0.5×10\^6/kg,1.5×10\^6/kg, 5.0×10\^6/kg CAR+ cells.
Study: NCT04725214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib With STUPP Regimen
Study: NCT06097507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: The consented patients will be given an information packet containing an infographic about the climate impact of inhalers, a letter explaining the option of changing inhalers (which clearly outlines that the Bricanyl Turbuhaler will not cost them more money than the Ventolin) and a pre-filled prescription for Bricanyl Turbuhaler.
Study: NCT05012605

Intervention type: OTHER
Intervention: Observation
Description: Observe physical function and sleep disorder symptoms following stroke
Study: NCT06354153

Intervention type: OTHER
Group type: OTHER
Intervention: Polarity Management Training Program
Description: 60 first-line nurse managers received a training program involving theoretical and practical sessions

Intervention type: OTHER
Group type: OTHER
Intervention: Polarity Management Training Program
Description: 60 first-line nurse managers received a training program involving theoretical and practical sessions
Study: NCT05180994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical infliximab
Description: Infliximab eye drops (10mg/ml) administered four (4) times per day for three (3) months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No topical infliximab
Description: No treatment with infliximab.
Study: NCT05888818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application
Description: A cold application (with a cold gel pack) will be applied to the upper part of the neck for 5 minutes.
Study: NCT06567210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCTi
Description: The program is composed of weekly online modules that include written information and interactive components such as schematics, images, videos, and questions. The content of the modules follows traditional and validated cognitive-behavioural therapy for insomnia protocols including sleep education, behavioural strategies (e.g., stimulus control, bedtime retraining, sleep hygiene), cognitive restructuration approaches (e.g., thought reappraisal, imagery, mindfulness), and relaxation practices (progressive muscle relaxation and autogenic training). In addition, further content aims to stabilize and amplify circadian rhythmicity through light exposure in the morning, daytime moderate physical activity, and evening time warm baths. Participants complete daily sleep diaries throughout the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General sleep information
Description: General sleep health information and access to daily sleep diaries during 8 weeks